Group 1 - Zhongce Rubber plans to use no more than 1 billion RMB of idle funds for cash management, investing in safe and liquid financial products with a maximum investment period of 12 months [1] - *ST Aowei received an administrative regulatory measures decision from the Liaoning Regulatory Bureau of the China Securities Regulatory Commission due to inaccuracies in performance forecasts and prior accounting errors [1] - Jiuzhoutong's subsidiary received a drug registration certificate for Dexamethasone Sodium Phosphate Injection, which is widely used for treating allergic and autoimmune inflammatory diseases [2] - Guosheng Technology signed a sales contract for photovoltaic modules worth 1.043 billion RMB with China General Nuclear Power Group, effective until December 31, 2025 [2][3] Group 2 - Taiankang's subsidiary received acceptance for the registration application of Glucosamine Sulfate Capsules, which are used for osteoarthritis treatment [3] - Jiuqiang Bio obtained a medical device registration certificate for a reagent used in the quantitative measurement of α-amylase in human serum and plasma [4] - Yao Pi Glass announced a production line shutdown for energy-saving upgrades and automation improvements, aiming for high-end manufacturing [4] - China Electric Power Construction signed new contracts worth 474 billion RMB in the first five months of 2024, with significant growth in wind and hydropower contracts [5] Group 3 - Huilong Pharmaceutical's clinical trial for HY0001a injection, targeting advanced solid tumors, received approval from the National Medical Products Administration [6] - Changshan Pharmaceutical's clinical trial for Aibennapeptide Injection for weight loss indications was approved [8] - Guoyao Modern's subsidiary passed the consistency evaluation for a generic drug, Cefoperazone Sodium Injection [9] - Wushang Group completed the payment for its second short-term financing bond, amounting to 500 million RMB [10] Group 4 - Jingda Co. received approval for its convertible bond application from the Shanghai Stock Exchange [11] - Guangting Information signed an investment cooperation agreement with Wuhan Optoelectronic Information Industry Park to establish an innovation laboratory for smart connected vehicles [12] - Darentang signed a share custody agreement for 100% equity of Tianjin Yiyuan [14] - CanSino received a drug registration certificate for its 13-valent pneumococcal polysaccharide conjugate vaccine [15] Group 5 - Heng Rui Medicine received clinical trial approval for six drugs targeting various treatment areas, including malignant tumors [16] - Kailong High-Tech obtained a commitment letter for a 25 million RMB stock repurchase loan from China Everbright Bank [18] - Southern Pump Industry's subsidiary plans to raise 105 million RMB through equity expansion [19] - Junxin Co. signed a strategic cooperation agreement with Changsha Digital Group to develop a waste incineration power generation project [21] Group 6 - Haixia Co. received a government subsidy of 103 million RMB, accounting for 39.93% of its audited net profit for 2024 [22] - Wanjitech obtained ten invention patents related to smart transportation and ETC [22] - Hubei Energy adjusted the transfer price for a 65% stake in a subsidiary to 50.32 million RMB [23] - Baida Group plans to use 285 million RMB of idle funds for entrusted wealth management [23] Group 7 - Dahao Technology's controlling shareholder plans to increase its stake in the company by 50 to 100 million RMB [24] - Guoxin Securities' asset purchase and related transaction received approval from the Shenzhen Stock Exchange [25] - New Industry received a medical device registration certificate for a carbon dioxide measurement kit [26] - ST Zhizhi's subsidiary received a government subsidy of 6.27 million RMB [27] Group 8 - China State Construction won the land use rights for a real estate development project in Shanghai for 8.195 billion RMB [29] - Huitong Energy's subsidiary invested 30 million RMB in a private equity fund focusing on key technologies in emerging industries [30] - Xiamen Tungsten's high-performance neodymium-iron-boron magnetic material project has commenced production [31] - Dongzhu Ecology's director plans to reduce his stake by up to 58,800 shares [32] Group 9 - Saiseng Pharmaceutical signed a 20 million RMB technology transfer contract for a new drug project [33] - Chutianlong's controlling shareholder reduced its stake by 1.1901 million shares [35] - Panlong Pharmaceutical's testing center received CNAS laboratory accreditation [36] - Ningbo Ocean plans to invest 2 billion RMB in building four container ships [37] Group 10 - YTO Express reported a 14.85% year-on-year increase in express product revenue for May, totaling 5.849 billion RMB [38] - Kangda New Materials intends to acquire at least 51% of Zhongke Huami's equity [39] - CATL plans to use up to 4.5 billion RMB of idle funds for cash management [40] - Changchun High-tech's subsidiary received approval for a clinical trial of a flu vaccine for seniors [41]
6月20日晚间重要公告一览